Tuberc Respir Dis.  2010 May;68(5):294-297.

A Case of Delayed Severe Hypersensitivity Reaction during Genexol-PM(R) Infusion

• Kim HK
• Kim SW
• Kang HW
• Kwon KJ
• Park HS
• Ryu YJ
• Lee JH
• Chun EM
• Cho YJ
• Chang JH

Abstract

Although Taxol(R) is one of the most successful drugs in current cancer chemotherapy against solid tumors, a major problem is hypersensitivity reactions that arises as a consequence of activation of the complement (C) system, "C activation-related pseudo-allergy". Most severe hypersenstivity reactions occur within the first few minutes of Taxol(R) administration, usually after the first or second dose. Here we report a case of a severe hypersensitivity reaction in a 72-year-old man undergoing Genexol-PM(R) infusion. Hypotension and polymorphic pruritic skin rash appeared 2 hours after the start of Genexol-PM(R) infusion (with an appropriate premedication). Treating with methylprednisolone, epinephrine and inotropic agents, reduced the hypotension and the skin rash disappeared. We report this case with a review of the literature.

Keyword

Hypersensitivity, Delayed; Anaphylaxis; Purpura; Paclitaxel

MeSH Terms

Aged
Anaphylaxis
Complement System Proteins
Epinephrine
Exanthema
Humans
Hypersensitivity
Hypersensitivity, Delayed
Hypotension
Methylprednisolone
Paclitaxel
Purpura
Complement System Proteins
Epinephrine
Methylprednisolone
Paclitaxel

Reference

1. Kloover JS, den Bakker MA, Gelderblom H, van Meerbeeck JP. Fatal outcome of a hypersensitivity reaction to paclitaxel: a critical review of premedication regimens. Br J Cancer. 2004. 90:304–305.

2. Lee C, Gianos M, Klaustermeyer WB. Diagnosis and management of hypersensitivity reactions related to common cancer chemotherapy agents. Ann Allergy Asthma Immunol. 2009. 102:179–187.

3. Kim TY, Kim DW, Chung JY, Shin SG, Kim SC, Heo DS, et al. Phase I and pharmacokinetic study of Genexol-PM, a cremophor-free, polymeric micelle-formulated paclitaxel, in patients with advanced malignancies. Clin Cancer Res. 2004. 10:3708–3716.

4. Kim DW, Kim SY, Kim HK, Kim SW, Shin SW, Kim JS, et al. Multicenter phase II trial of Genexol-PM, a novel Cremophor-free, polymeric micelle formulation of paclitaxel, with cisplatin in patients with advanced non-small-cell lung cancer. Ann Oncol. 2007. 18:2009–2014.

5. Sendo T, Sakai N, Itoh Y, Ikesue H, Kobayashi H, Hirakawa T, et al. Incidence and risk factors for paclitaxel hypersensitivity during ovarian cancer chemotherapy. Cancer Chemother Pharmacol. 2005. 56:91–96.

6. Ring J, Seifert J, Messmer K, Brendel W. Anaphylactoid reactions due to hydroxyethyl starch infusion. Eur Surg Res. 1976. 8:389–399.

7. Gilbar P, Ridge A. Dexamethasone prophylaxis for paclitaxel hypersensitivity. J Oncol Pharm Pract. 2002. 8:81–87.

8. Szebeni J. Complement activation-related pseudoallergy: a new class of drug-induced acute immune toxicity. Toxicology. 2005. 216:106–121.

9. Szebeni J, Alving CR, Savay S, Barenholz Y, Priev A, Danino D, et al. Formation of complement-activating particles in aqueous solutions of Taxol: possible role in hypersensitivity reactions. Int Immunopharmacol. 2001. 1:721–735.

10. Judge A, McClintock K, Phelps JR, Maclachlan I. Hypersensitivity and loss of disease site targeting caused by antibody responses to PEGylated liposomes. Mol Ther. 2006. 13:328–337.

11. Szebeni J, Baranyi L, Savay S, Lutz HU, Jelezarova E, Bunger R, et al. The role of complement activation in hypersensitivity to PEGylated liposomal doxorubicin (Doxil®). J Liposome Res. 2000. 10:467–481.

12. Kim SC, Kim DW, Shim YH, Bang JS, Oh HS, Kim SW, et al. In vivo evaluation of polymeric micellar paclitaxel formulation: toxicity and efficacy. J Control Release. 2001. 72:191–202.